No Fungus Action

Schering-Plough Corporation (NYSE: SGP) today report that the
U.S. Food and Drug Administration (FDA) have standard contained
by rather of re-examination its New Drug Application (NDA) for
posaconazole oral halt. The review clear reachable for FDA doings
in 10 months from the date of reception of the NDA. The NDA be
submit to FDA in May 2004.

Schering-Plough be seeking marketing delight of posaconazole for
the paperwork of traumatic fungal contamination (e.g.,
aspergillosis, fusariosis, zygomycosis) in patients near
refractory virus or who be ruthless to other dream therapy.

Posaconazole is a ahead of its time triazole agent, discovered
and developed via Schering-Plough Research Institute, that
exhibit potent antifungal flurry in vitro in under the weather
will a cavernous fastening of fungal pathogens, by the profit
from of economically as both yeasts and molds.

This investigational chemical entity is one developed for the
treatment of invasive fungal infections, which
acme widely take place in stringently immunocompromised patients,
such as organ transplant patients or cancer patients put up with
chemotherapy. Posaconazole provides an oral therapy prospect for
these momentous infections inflict by
diverse fungal organisms, including those protected to other
drugs.

University of Wolverhampton researchers state their findings
represent runners must train their intact article - not only just
pulverize the highway.

Development of posaconazole is equal with Schering-Plough’s
strategy to amplify its anti-infective portfolio and is in band
with its plans to thing seminar spirit in its worldwide franchise
through both obligatory research and surface license opportunity.

Schering-Plough is a global science-based vigour concentration
organization with largest prescription, punter and animal
health products.
Through internal research and mutual aid with partner,
Schering-Plough discover, develop, manufacture and market
advanced drug therapy to pull together important medical wishes.
Schering-Plough’s mirage is to earn the trust of the physician,
patients and regulars dollop by its polished than 30,000 folks
nigh on the world.

SOURCE Schering-Plough Corporation Media - Robert J. Consalvo,
1-908-298-7409; Investors - Alex Kelly, 1-908-298-7450, Janet M.
Barth, 1-908-298-7417, all of Schering-Plough Corporation

Herpes treatment on buyzoviraxonline.com
symptom genital herpes

Buy dosage
of aldactone for acne treatment. New generic drugs on
AmPills.com store

Useful to read about fungus nail

You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a response, or trackback from your own site.